Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Sergio Traversa is Chief Executive Officer at Relmada Therapeutics. OQRO lists 6 transactions filed with the SEC under this name, the latest on Aug 28, 2025, each linked to the official Form 4.
Chief Executive Officer
Disclosures on record
6
Companies involved
1
2 buys, median +153.3 pts vs S&P 500, beat it 2 of 2 times.
Average +153.3 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed May 20, 2025 to Aug 28, 2025, measured from the first close after the filing. Past results, not a forecast.
2 purchases disclosed; 100% of the 2 measured at 90 days finished ahead of the index.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
Relmada TherapeuticsRLMD
6 disclosures · May 2025 – Aug 2025 · 6 bought
Aug 27, 2025Bought~$87Kdisclosed Aug 28
DetailsOfficial recordAug 26, 2025Bought~$50Kdisclosed Aug 28
DetailsEqual weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Aug 28, 2025Bought~$41K
DetailsOfficial recordMay 20, 2025Bought~$82K
DetailsOfficial recordMay 16, 2025Bought~$77Kdisclosed May 20
DetailsOfficial recordMay 19, 2025Bought~$15Kdisclosed May 20
DetailsOfficial recordAs of the latest filing on , Sergio Traversa reported holding 1,000,000 shares of Relmada Therapeutics (RLMD), worth about $4.21M at the last close of $4 (Nov 13, 2026).
Relmada Therapeutics's proxy statement reports total compensation of $8.89M for Sergio Traversa for fiscal year 2025, after $1.8M for 2024. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received. Proxy statement filed Apr 17, 2026
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Relmada Therapeutics RLMD | 1,000,000 | 1.00M direct | $4 | $4.21M | Aug 28, 2025 |
Is this Sergio Traversa’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Sergio Traversa bought shares on the open market in 2015, 2016, 2022, 2024 and 2025 across 2 companies. Sales in 2 of the 12 years since 2015.
Sergio Traversa reported 25 open-market purchases and 24 sales since 2015; purchases in 5 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | $353K6×6 trades | — |
| 2024 | $782K6×6 trades | — |
| 2022 | $116K1×1 trade | $560K5×5 trades |
| 2021 | — | $1.73M19×19 trades |
| 2016 | $6.1K2×2 trades | — |
| 2015 | $58K10×10 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Aug 28, 2025, Sergio Traversa reported holding 1,000,000 shares of Relmada Therapeutics (RLMD). At the last close of $4 on Nov 13, 2026, that is about $4.21M. This is the stake disclosed in filings, not a net worth.
Relmada Therapeutics's proxy statement reports total compensation of $8.89M for Sergio Traversa for fiscal year 2025, after $1.8M for 2024. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received.
Sergio Traversa bought shares on the open market in 2015, 2016, 2022, 2024 and 2025 across 2 companies. Sales in 2 of the 12 years since 2015.
In SEC filings since 2015: the latest open-market purchase is from 2025; the latest open-market sale is from 2022.
2 companies: Relmada Therapeutics (RLMD, 2015–2025), Actinium Pharmaceuticals (ATNM, 2016).
Sergio Traversa reported 23 open-market purchases and 24 sales here, 2015 to 2025.
Sergio Traversa reported 2 open-market purchases and 0 sales here, 2016.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
